Moderna's mRNA Flu Vaccine Receives FDA Approval for Older Adults

The U.S. FDA has approved Moderna's mFlusiva, the first mRNA-based seasonal flu vaccine, for individuals aged 50 and above. This approval represents a significant advancement in influenza vaccine technology, potentially offering a new option for protection against the virus in an at-risk demographic.